Daro + ADT and docetaxel in mHSPC: RW Evidence from the TRIDA Study of SOGUG 🇪🇸 #ESMO26 @urotoday @Ricardo62949193

Zach Klaassen· @zklaassen_md · X·2026-10-23 18:54· 2 天前评分70

正文 · 原文

mFU: 11 mos
📌16.2% progressed to CRPC
📌mOS NR, 18 mo probability of survival: 86.5%
📌48.5% PSA <= 0.2
📌83.3% disease control
📌Similar safety to ARASENS

601 浏览 · 9 赞 · 8 转发 · 0 回复

会议摘要

2300TIPNCT07365995 NCT07365995 NCT07365995按 Metastatic prostate cancer 对上

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：Zach Klaassen · x.com